Tested Applications
| Positive IHC detected in | human nephroblastoma tissue, human prostate cancer tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Recommended dilution
| Application | Dilution |
|---|---|
| Immunohistochemistry (IHC) | IHC : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
55449-1-AP targets NOV in IHC, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
Peptide Predict reactive species |
| Full Name | nephroblastoma overexpressed gene |
| Calculated Molecular Weight | 39 kDa |
| GenBank Accession Number | NM_002514 |
| Gene Symbol | NOV |
| Gene ID (NCBI) | 4856 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | P48745 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Publications
What published studies show
I'll search for the citations of this antibody.I found 1 citation for NOV Polyclonal antibody (55449-1-AP).
Citation Summary for 55449-1-AP (NOV Polyclonal antibody)
- Antibody name: NOV/CCN3 Polyclonal antibody
- Catalog number: 55449-1-AP
- Total citation count: 1
- Journal: Journal of Cellular and Molecular Medicine (J Cell Mol Med), 2019
- Application used: IHC
- Research field: Cartilage biology — investigating the protective role of NOV/CCN3 in cartilage by inhibiting the PI3K/AKT/mTOR signaling pathway, relevant to chondroprotection and osteoarthritis research.
| Species | Application | Title |
|---|---|---|
J Cell Mol Med NOV/CCN3 induces cartilage protection by inhibiting PI3K/AKT/mTOR pathway. |







